Name

T-cell large granular lymphocytic leukemia

ICD-O-3 Morphology

9831/3: T-cell large granular lymphocytic leukemia
Effective 2010 and later

Reportable

for cases diagnosed 2010 and later

Primary Site(s)

C421
Primary site must be bone marrow (C421)

Abstractor Notes

(This neoplasm is reportable for cases diagnosed 2010 and later.)

Many patients receive no treatment, some receive aspirin, others corticosteroids, or they may receive chemotherapy in low doses. Some patients have a splenectomy.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Grade

Not Applicable

Module Rule

None

Alternate Names

Chronic NK-cell lymphocytosis
Chronic NK-large granular lymphocyte (LGL) lymphoproliferative disorder
CLPD-NK
Indolent large granular NK-cell lymphoproliferative disorder
Large granular lymphocytosis, NOS
NK-cell LGL lymphocytosis
NK-cell large granular lymphocytic leukemia
NK-cell lineage granular lymphocyte proliferative disorder
T-cell granular lymphocytic leukemia
T-cell large granular lymphocytosis
T-cell lymphoproliferative disease of granular lymphocytes
T-gamma lymphoproliferative disease [OBS]
T-LGL

Definition

T-cell large granular lymphocytic leukemia (T-LGLL) is a heterogenuous disorder characterized by a persistent (> 6 months) increase in the number of peripheral blood large granular lymphocytes (LGLs) without a clearly identified cause.

Chronic lymphoproliferative disorder of NK cells (CLPD-NKs) are rare and heterogenuous. They are characterized by a persistent (> 6 months) increase in the peripheral blood NK-cell count without a clearly identified cause. It is difficult to distinguish between reactive and neoplastic conditions without highly specialized techniques. CLPD-NK is a proliferation of NK cells associated with a chronic clinical course and is considered a provisional entity.

Definitive Diagnostic Methods

Bone marrow biopsy
Genetic testing
Immunophenotyping
Peripheral blood smear

Genetics Data

STAT3 mutations
TR genes are clonally rearragned

Immunophenotyping

CD2+ (expression/negative)
CD3+ (expression/negative)
CD4+/- (positive and negative)
CD8+/- (positive and negative)
CD16+ (expression/negative)
CD57+ (expression/negative)
Granzyme B+ (expression/negative)
Granzyme M+ (expression/negative)
KIR+ (expression/negative)
TCR+ (expression/negative) cytotoxic T cells (alpha beta and gamma delta)

Treatments

Chemotherapy
Other therapy
Surgery

Transformations to

None

Corresponding ICD-9 Codes

204.8 Other lymphoid leukemia

Corresponding ICD-10 Codes

C91.7 Other lymphoid leukemia

Corresponding ICD-10-CM Codes (U.S. only)

C91.Z Other lymphoid leukemia (effective October 01, 2015)

Signs and Symptoms

Anemia
Cytopenia
Lymphocytosis
Neutropenia
Rheumatoid arthritis
Splenomegaly (moderate)
Thrombocytopenia

Diagnostic Exams

Blood chemistry studies
Cytogenetic analysis
Flow cytometry
Immunohistochemistry
Immunophenotyping
Peripheral blood smear

Progression and Transformation

None

Epidemiology and Mortality

Age: 45-75 years (rare before 25 years)
Incidence: 2-3% of all mature lymphocytic leukemias
Sex: no male or female predominance
Survival: indolent course over prolonged period, mortality associated with cytopenias (mostly neutropenia)

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Mature T- and NK-cell neoplasms
Pages: 348-352

International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013.
Section: ICD-O-3.1 (2011) Morphological Codes
Pages: http://codes.iarc.fr/codegroup/2
Glossary